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Human type III iodothyronine deiodinase (D3) catalyzes the
conversion of T4 to rT3 and of T3 to 3, 3-diiodothyronine (T2)
by inner-ring deiodination. Like types I and II iodothyronine
deiodinases, D3 protein contains selenocysteine (SeC) in the
highly conserved core catalytic center at amino acid position
144. To evaluate the contribution of SeC144 to the catalytic
properties of D3 enzyme, we generated mutants in which cys-
teine (D3Cys) or alanine (D3Ala) replaces SeC144 (D3wt). COS
cells were transfected with expression vectors encoding
D3wt, D3Cys, or D3Ala protein. Kinetic analysis was per-
formed on homogenates with dithiothreitol as reducing co-
factor. The Michaelis constant of T3 was 5-fold higher for
D3Cys than for D3wt protein. In contrast, the Michaelis con-
stant of T4 increased 100-fold. The D3Ala protein was enzy-
matically inactive. Semiquantitative immunoblotting of ho-
mogenates with a D3 antiserum revealed that about 50-fold
higher amounts of D3Cys and D3Ala protein are expressed
relative to D3wt protein. The relative substrate turnover num-
ber of D3Cys is 2-fold reduced for T3 and 6-fold reduced for T4
deiodination, compared with D3wt enzyme. Studies in intact
COS cells expressing D3wt or D3Cys showed that the D3Cys
enzyme is also active under in situ conditions. In conclusion,
the SeC residue in the catalytic center of D3 is essential for
efficient inner-ring deiodination of T3 and in particular T4 at
physiological substrate concentrations. (Endocrinology 144:
2505–2513, 2003)
T4, THE MAIN secretory product of the thyroid gland,undergoes enzymatic outer-ring deiodination in pe-
ripheral tissues to T3 catalyzed by the deiodinases type I (D1)
and type II (D2) as well as inner-ring deiodination (IRD) to
rT3 catalyzed by the deiodinase type III (D3; Refs. 1–4). In
fact, D3 is the major T4 and T3 inactivating enzyme by cat-
alyzing the conversion of T4 to rT3 and T3 to T2 by IRD (1–5).
In rodents and humans, D3 activity was found in brain,
skin, (failing) heart, placenta, uterus, and several fetal tissues
such as liver and brain (6–18). In Xenopus laevis tadpoles, D3
activity is present in limb buds, retina, and tail in various
stages of development (19–20). Also in various other species,
such as chicken and fish, D3 activity is present in brain, liver,
and skin (21–23). Recently very high levels of D3 activity
were described in infantile hemangiomas causing severe hy-
pothyroidism (24).
Thyroid hormone is a major physiological regulator of
brain development. The presence of D3 in organs such as the
brain is thought to play a role in the local fine-regulation of
intracellular T3 levels, whereas its presence in placenta,
uterus, and fetal organs may protect fetal brain tissue against
premature exposure to T3 during early stages of develop-
ment (2, 10–13, 16, 17, 25–29).
The D3 protein is a selenoprotein, containing a selenocys-
teine residue (SeC) in the catalytic center (30–36). Comple-
mentary DNAs from several species that code for the D3
protein have been isolated, and they contain a UGA stop
codon within the open reading frame that is translated as SeC
(32–36). The presence of an SeC insertion sequence element
in the 3-UTR of the mRNA is essential for SeC incorporation
at the UGA codon, which otherwise would function as a stop
codon (37).
The catalytic mechanism of D3 seems to be different from
that of D1 but similar to that of D2 enzyme. Outer-ring
deiodination of T4 or rT3 by D1 enzyme exhibits ping-pong
(bi)substrate kinetics with T4 or rT3 and the thiol-containing
cofactor as cosubstrates (38, 39). The D2 and D3 enzymes
exhibit sequential reaction kinetics, suggesting that T4 and
the thiol-containing cofactor must interact with the enzyme
simultaneously before reaction takes place (7, 18, 38, 40). The
SeC residue in the catalytic center is essential for maximal
catalytic efficiency of deiodinases (32–33, 40–42). In D1, mu-
tation of SeC to leucine or alanine eliminates deiodinase
activity, whereas its mutation to cysteine (Cys) raises the
apparent Michaelis constant (Km) for rT3 3-fold and reduces
the substrate-turnover number about 100-fold (41). Remark-
ably, in D2 mutation of SeC to Cys raises the apparent Km for
T4 about 1000-fold, whereas the substrate-turnover number
is reduced only 10-fold (40, 42). For D3 it was shown that
substitution of SeC with leucine eliminates deiodinase ac-
tivity, whereas substitution with Cys (D3Cys) reduced en-
zyme activity (32–33). However, the D3Cys protein was not
further characterized with regard to substrate interaction,
substrate turnover number, and catalytic mechanism.
The present studies were undertaken to elucidate the func-
tional role of the SeC residue in the catalytic center of D3
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protein in more detail. We have examined effects of the
SeC144 to Cys (D3Cys) or SeC144 to Ala (D3Ala) mutation
in human D3 protein on substrate and cofactor interaction as
well as on the substrate turnover number.
Materials and Methods
Materials
Nonradioactive iodothyronines were obtained from Henning (Berlin,
Germany) or Calbiochem (San Diego, CA). [3-125I]T3 (2000 mCi/mol)
and [3,5-125I]T4 (1200 mCi/mol) were either obtained from Amer-
sham Pharmacia Biotech (Little Chalfont, Buckinghamshire, UK) or pre-
pared by radioiodination of 3,5-T2 and 3,3,5-T3, respectively, using the
chloramine-T method as described (43). Before each experiment, the
radiolabeled iodothyronines were purified on Sephadex LH-20 columns.
Radioactively labeled N-bromoacetyl-T3 (BrAc[
125I]T3) and N-bromo-
acetyl-T2 (BrAc[125I]T2) were synthesized from bromoacetylchloride and
[3-125I]T3 or [3-
125I]T2 as described (44). Nonradioactive N-bromo-
acetyl-T3 (BrAcT3) was obtained from Henning. Gold thioglucose (GTG)
and iodoacetate (IAc) were obtained from Sigma (St. Louis, MO). Di-
thiotreitol (DTT) was obtained from ICN Biochemicals Inc. (Costa Mesa,
CA). Pyrococcus furiosus thermostable DNA polymerase and DpnI re-
striction endonuclease were obtained from Promega Corp. (Madison,
WI). XL-10 ultracompetent Escherichia coli cells were obtained from Strat-
agene (La Jolla, CA). Synthetic oligonucleotides were ordered from
Invitrogen-Life Technologies, Inc. (Glasgow, UK).
Site-directed mutagenesis
A human D3 expression vector (pcDNA3-D3) containing a 1.9-kb
insert including 35 nucleotides of the 5-untranslated region (nucleotides
185-2066 in Ref. 34) was used as template for site-directed mutagenesis
via the circular mutagenesis procedure, followed by selection for mu-
tants by DpnI digestion (45). Overlapping sense and antisense primers
containing the nucleotide changes needed to produce the SeC144Cys D3
mutant cDNA.
The (sense 5 TTCGGAAGCTGCACCTGCCCACCGTTCATGGCG)
and SeC144Ala mutant cDNA (sense 5TTCGGAAGCTGCACCGCAC-
CACCGTTCATGGCG) were used in circular mutagenesis reactions
with 50 ng plasmid template and 2 U P. furiosus DNA polymerase (45).
The cycling protocol consisted of 30 sec at 95 C, 1 min at 55 C, 14 min
at 68 C for 18 cycles using a model 480 PCR machine (Perkin-Elmer,
Norwalk, CT). The reaction products were incubated with 10 U DpnI
enzyme for 2 h at 37 C and immediately transformed to competent E.
coli XL-10 cells according to manufacturer’s instructions. Plasmid DNA
isolated from up to four clones was sequenced on a model 310 DNA
sequencer (ABI, Foster City, CA) to verify that the desired mutation had
been generated and no spurious mutations had occurred during am-
plification (46). Plasmids were maintained in E. coli DH5 cells and
purified with QIAfilter cartridges (QIAGEN, Hilden, Germany).
During sequencing of the wt D3 cDNA, we noted that codon 53
encodes glutamine instead of lysine as previously reported (Ref. 34;
GenBank accession no. S79854). A more recent GenBank entry
(XM007250) also describes a glutamine residue at codon 53.
Expression of D3 protein
The wt and mutant D3 enzymes were expressed in COS-1 cells or
human embryonic kidney (HEK)-293 cells (65-cm2 dishes) after dieth-
ylaminoethyl-dextran-mediated transfection of the expression vectors
(40, 47). COS-1 cells were grown in DMEM-Ham’s F-12 medium con-
taining 10% fetal calf serum (Life Technologies, Inc.) and 40 nm sodium
selenite. Two days after transfection, the cells were rinsed with PBS and
collected in 0.25 ml 0.1 m phosphate (pH 7.2), 2 mm EDTA buffer;
sonicated; aliquoted; and stored at 80 C.
Assay of IRD activity in cell homogenates
This assay is based on the determination of product formation (125I-
labeled T2 or rT3) by reverse-phase HPLC analysis of reaction mixtures
containing outer-ring-labeled T3 or T4 (1, 17).
Incubations contained about 200,000 cpm labeled T3 or T4 with vary-
ing amounts of unlabeled substrate (T3 or T4) and cell homogenate (5–10
g protein) in a final volume of 0.1 ml P100E2 buffer (0.1 m phosphate,
pH 7.2; 2 mm EDTA) and varying amounts of DTT (0.1–30 mm). In some
experiments a pH profile was obtained using 0.1 m phosphate, 2 mm
EDTA buffers of pH 6.0–8.0. Mixtures were incubated for 60 min at 37
C, whereafter the reaction was stopped by addition of 0.1 ml ice-cold
methanol. After centrifugation, 0.1 ml was mixed with 0.1 ml 0.02 m
ammonium acetate (pH 4.0), and 0.1 ml (equivalent to 25-l reaction
volume) of the mixture was applied to a 250  4.6 mm Symmetry C18
column connected to an Alliance HPLC system (Waters Chromatogra-
phy Division, Millipore Corp., Milford, MA) and eluted with a 15-min
linear gradient of acetonitrile (28–42%) in 0.02 m ammonium acteate (pH
4) at a flow rate of 1.2 ml/min. Radioactivity in the eluate was monitored
online using a Radiomatic A-500 flow scintillation detector (Packard,
Meriden, CT).
Homogenate protein was adjusted to limit substrate consumption to
less than 30%. Enzymatic deiodination was corrected for nonenzymatic
deiodination by determining the amount of 125I-labeled T2 or rT3 formed
in blank incubations with homogenates of nontransfected cells.
Assay of IRD activity in intact transfected COS cells
COS cells were cultured in 6-well plates (10 cm2/well) and transfected
with 0.2 or 2 g plasmid per well as described (40). One day after
transfection, cell monolayers were washed with serum-free DMEM/F12
medium and cultured for an additional 24 h in serum-free DMEM/F12
supplemented with 40 nm sodium selenite, to which was added [3,5-
125I]T4 or [3-
125I]T3 (1  10
6 cpm/ml) plus 1–1000 nm unlabeled T4 or
T3. After 20–24 h the medium was harvested and extracted with ice-cold
methanol (1:1). After centrifugation, the extract was mixed with 0.02 m
ammoniumacetate (pH 4), and 0.1 ml of the mixture was analyzed with
the same HPLC system as described. The column was eluted with a
20-min gradient of 24–29% acetonitrile followed by a 6-min gradient of
29–50% acetonitrile in 0.02 m ammonium acetate (pH 4). This gradient
provides improved separation of sulfated iodothyronines from nonsul-
fated iodothyronines.
Polyclonal antiserum production and Western blotting
Polyclonal antisera were raised in rabbits by Eurogentec SA (Herstal,
Belgium) after conjugation of the synthetic peptide (C)RYDEQLH-
GARPRRV (human D3 amino acid residues 265–278) to keyhole limpet
hemocyanin. Antiserum (designated 677) from the final bleed was used
without further purification.
COS cell homogenates (20–30 g protein) were separated on 12%
SDS-PAGE gels in the Mini-Protean II cel (Bio-Rad Laboratories, Inc.,
Hercules, CA) according to the manufacturer’s instructions. After elec-
trophoresis the gels were positioned on nitrocellulose membranes
(Hybond-C pure, Amersham Pharmacia Biotech) and placed in a mini-
transblot cell (Bio-Rad Laboratories, Inc.) filled with buffer (25 mm
Tris-HCl, pH 8.3; 150 mm glycine; and 20% vol/vol methanol). The
transfer was performed for 1 h at 100 V.
Membranes were blocked with 5% (wt/vol) nonfat milk in PBS with
0.1% Tween 20 (PBS-Tween) for 1 h at 37 C and thereafter incubated with
antiserum 677 at a 1:500 dilution in 5% (wt/vol) milk in PBS-Tween
overnight at 8 C. Blots were washed 2  15 min with 5% (wt/vol) milk
in PBS-Tween and 2 15 min with PBS-Tween, followed by incubation
with peroxidase-conjugated secondary antibody (A0545, 1:16,000,
Sigma) in 5% (wt/vol) milk in PBS-Tween for 2 h. After washing as
described, the blot was developed with a homemade chemilumines-
cence system (48) consisting of 0.7m p-coumaric acid, 1.25 mm luminol,
and 0.01% hydrogen peroxide in 0.1 m Tris HCl (pH 8.5), and exposed
to Hyperfilm ECL film (Amersham) for 5–15 min.
To compare the relative amounts of enzyme expressed between wild-
type and mutant D3, the mutant enzyme was diluted in cell lysate
derived from nontransfected COS cells. The density of the D3 bands was
quantified by densitometry.
Affinity labeling of D1 and D3 protein with BrAc[125I]T3
BrAc[125I]T3 (1500 mCi/mol) was synthesized as described (44), and
HPLC analysis demonstrated that the purity was at least 85% with
unreacted [125I]T3 as the main contaminant. Unlabeled BrAcT3 was also
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analyzed by HPLC and found to be more than 90% pure. The concen-
tration was determined by mixing with a T3 internal standard and online
monitoring of the eluates with a photodiode array detector, taking into
account that the molar extinction coefficient of BrAcT3 is very close to
that of T3 in the far UV (49).
Solutions of BrAc[125I]T3 (200,000 cpm, 0.06 pmol) in ethanol were
pipetted into microcentrifuge tubes, and the solvent was evaporated by
a stream of nitrogen. After addition of 25 l P100E2D10 (0.1 m sodium
phosphate; 2 mm EDTA; 10 mm DTT, pH 7.2) and vortexing, the cell
homogenates (100–150 g protein) were added in a total volume of 50
l P100E2D10. The mixtures were incubated for 10–20 min on ice, at
room temperature or 37 C. Reactions were terminated by addition of
SDS-PAGE gel-loading buffer, and samples were analyzed by SDS-
PAGE (12% gel) followed by autoradiography to BioMax MS film
(Kodak, Rochester, NY) at 70 C with intensifying screen (50–52).
Alternatively, the reactions were terminated by the addition of ice-
cold methanol. After centrifugation the protein-free supernatant was
mixed with 0.1% trifluoracetic acid (pH 2) and analyzed with the same
HPLC system as described. The column was eluted with a 20-min gra-
dient of 40–60% acetonitrile in 0.1% trifluoracetic acid. Retention times
for BrAc-iodothyronines were determined by incubation of BrAc[125I]T3
and BrAc[125I]T2 with homogenates of nontransfected COS cells in
P100E2D10 buffer and HPLC analysis as described.
Results
Analysis of mutant D3 enzymes in vitro
To define the role of SeC144 with regard to the catalytic
properties of D3 enzyme, we generated mutants in which
cysteine (D3Cys) or alanine (D3Ala) replaced SeC144. The
substitution of cysteine for SeC essentially replaces the se-
lenium of SeC with sulfur. Alanine was chosen as a control
because it has an inert side chain. COS cells were transfected
with expression vectors encoding the D3wt, D3Cys, or D3Ala
enzymes, and kinetic analysis with T3 or T4 was performed
on homogenates in the presence of 0.3–10 mm DTT (Figs. 1
and 2, and Table 1).
For the D3wt and D3Cys enzyme as well as D3 activity of
human placenta microsomes, Lineweaver-Burk plots of T3
deiodination at varying reducing cofactor (DTT) concentra-
tions yielded a set of intersecting lines (Fig. 1). The D3 protein
exhibits sequential reaction kinetics as was shown previously
(7, 18), suggesting that T3 and the thiol-containing cofactor
must interact with the enzyme simultaneously before reac-
tion takes place. In the presence of 10 mm DTT, the Km of T3
was 5-fold higher for the D3Cys enzyme than for the D3wt
enzyme, whereas the maximal velocity (Vmax) increased
about 25-fold (Table 1). The D3Ala enzyme was inactive.
When T4 was used as substrate, the Km was 50–100 times
higher for the D3Cys enzyme than for the D3wt enzyme at
DTT concentrations of 1 mm or higher. In the case of T4, Vmax
increased only 8-fold (Fig. 2 and Table 1). The Vmax/Km ratios
were calculated as a measure of the efficiency by which the
D3wt and D3Cys enzyme deiodinate the substrates T3 and T4.
The D3wt enzyme deiodinates T3 and T4 with equal effi-
ciency as reflected in the similar Vmax/Km ratios. In contrast,
the D3Cys enzyme strongly prefers T3 above T4 because the
Vmax/Km ratio for T3 is 40-fold higher. In the absence of DTT,
no deiodination of T3 or T4 could be measured by D3wt or
D3Cys enzyme. Maximal enzyme activity was observed at 10
mm DTT, whereas at higher DTT concentrations (30 mm),
the activity was reduced (not shown). No outer-ring deio-
dination of T3, T4, or rT3 by D3wt or D3Cys enzyme was
detected.
Selenoenzymes such as thioredoxin reductase, glutathione
peroxidase, formate dehydrogenase, and iodothyronine
deiodinases are inhibited by organic gold compounds and
IAc (1–5, 53–56). GTG or aurothioglucose is a competitive
inhibitor of T3 deiodination by D3 (34). Under the conditions
used (1 nm T3, 10 mm DTT), the IC50 value for inhibition by
GTG of D3wt enzyme was about 1 m. Interestingly, the
D3Cys enzyme is not insensitive to GTG, although the IC50
value increased to about 30 m (Fig. 3). Under the same
FIG. 1. Lineweaver-Burk plots of T3 deiodination at various DTT
concentrations catalyzed by D3wt (A), D3Cys (B), and D3 in human
placenta microsomes (C). Each data point is the average of closely
agreeing duplicate determinations, and the experiment was per-
formed twice on different homogenates with similar results.
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experimental conditions, both the D3wt and D3Cys enzymes
were essentially insensitive to IAc (IC50  1 mm).
The decreased catalytic activity of D1 and D2 mutant en-
zymes in which Cys substitutes for SeC has been attributed
to the reduced dissociation (deprotonation) of the sulfydryl
moiety at physiological pH and thus to the diminished nu-
cleophilic character of the catalytic center (41, 42). By com-
paring the actual pH profiles of D3wt and D3Cys enzyme
(Fig. 4), no shift to more alkaline pH values for D3Cys en-
zyme was observed, despite the different pK values (5.2 vs.
9.0) of the selenol and sulfhydryl moieties in free SeC and Cys
(57, 58).
Quantitation of D3 enzymes and estimation of substrate
turnover number
To quantitate the effect of the substitution of Cys for SeC
on the substrate turnover number, it is necessary to estimate
the absolute or relative expression levels of protein. We per-
formed semiquantitative Western blotting using a D3 anti-
serum on homogenates of COS cells expressing D3wt or
D3Cys protein (Fig. 5). Comparison of the densities of the
approximately 34-kDa D3 protein band indicated that the
amount of D3Cys protein is 40- to 50-fold greater than
the amount of D3wt protein. Also, the amount of D3Ala
protein expressed was about 50-fold greater than D3wt pro-
tein (not shown). Using an estimate that 50-fold higher quan-
tities of D3Cys protein are expressed relative to D3wt protein
and using the Vmax values obtained (Table 1), our results
indicated that the substrate turnover number of D3Cys en-
zyme is 2-fold reduced for T3 and 6-fold reduced for T4
deiodination, compared with D3wt enzyme.
To calculate the absolute substrate turnover number of D3,
it is necessary to determine the quantity of the transiently
expressed protein. BrAc[125I]T3 has proven to be a very useful
affinity label of D1 protein, and saturation analysis of the
progressive labeling of D1 protein with increasing concen-
trations of BrAcT3 allowed the determination of D1 expres-
sion levels (41, 50). We therefore decided to investigate the
possibility of using BrAc[125I]T3 to specifically label D3 pro-
tein in COS cell homogenates.
The deiodination of T3 (1 nm [
125I]T3, 10 mm DTT) could
be completely inhibited with BrAcT3, indicating that BrAcT3
interacts with the D3 enzyme. The IC50 values were about 3
nm for D3wt enzyme and about 30 nm for D3Cys enzyme (not
shown). After incubation of homogenates with BrAc[125I]T3
followed by SDS-PAGE, a labeled protein of 34 kDa was
observed in homogenates containing D3Cys protein and a
weakly labeled protein of the same molecular size was
present in homogenates containing D3wt protein. Especially
after prolonged autoradiography, a weakly labeled protein
with slightly higher molecular mass than D3 was visible in
homogenates of nontransfected COS cells (Fig. 6A). The
D3Ala protein could not be labeled with BrAcT3, despite the
fact that the expression level is equally high as that of D3Cys
protein. This indicates that deiodinase activity is essential for
labeling with BrAcT3 and probably the SeC144 or Cys144
residues are the targets for labeling by BrAcT3. The same
affinity labeling experiments were done with homogenates
of HEK-293 cells transfected with D3wt or D3Cys vectors.
The activity of D3wt in HEK cell homogenates was 1.5-fold
higher than in COS cell homogenates. The results of the
labeling experiments with HEK cell homogenates were sim-
ilar to those with COS cell homogenates. Both for COS and
HEK cell homogenates, about 0.5% of the added BrAc[125I]T3
was incorporated into D3wt protein and about 1.5% in D3Cys
protein as determined by SDS-PAGE followed by counting
of radioactivity in gel slices. Altogether the labeling of D3
protein was weak, compared with that of rat D1 protein.
Given the intense labeling of D1 protein, it is unlikely that
COS cell proteins interfere with the labeling of D3 by BrAcT3
(Fig. 6A).
Another possible explanation for the differential labeling
of D1 and D3 might be degradation or deiodination of
BrAcT3 by the D3 enzyme. In a series of experiments, the
labeling reactions were terminated by addition of ice-cold
methanol. The protein-free supernatants were subsequently
analyzed by reverse-phase HPLC (see Materials and Methods).
The HPLC analysis revealed a shift of radioactivity to more
polar components, most likely as a consequence of inner-ring
deiodination of BrAc[125I]T3 to BrAc[
125I]T2 and BrAc[
125I]T1
by D3wt and D3Cys enzyme (Fig. 6B). Apart from D3 in COS
or HEK cell homogenates, D3 in human placental micro-
somes also caused inner-ring deiodination of BrAcT3. Nei-
FIG. 2. Lineweaver-Burk plots of T4 deiodination at various DTT
concentrations catalyzed by D3wt (A) or D3Cys (B) enzyme. Each data
point is the average of closely agreeing duplicate determinations, and
the experiment was performed twice.
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ther inner-ring nor outer-ring deiodination of BrAc[125I]T3 by
D1 or D2 enzymes could be detected (not shown). Attempts
to reduce the inner-ring deiodination of BrAcT3 by lowering
the DTT concentration to 0.1 mm or 1 mm instead of 10 mm
increased incorporation of radioactivity in the various pro-
teins but did not increase the relative incorporation of ra-
dioactivity in D3 protein as analyzed by SDS-PAGE (not
shown). Because of the rather weak labeling of D3, a reliable
estimation of D3 content by saturation analysis was not pos-
sible. Under the most favorable conditions (1 mm DTT at 37
C), 0.5% of the added BrAc[125I]T3 was incorporated into
D3wt protein and about 2% in D3Cys protein. By compar-
ison, 6% of the added BrAc[125I]T3 was incorporated into rat
D1wt protein.
Deiodination by wild-type D3, D3Cys, and D3Ala protein in
intact cells
The D3Cys enzyme is active in vitro in the presence of
excess iodothyronine substrate and DTT. An important ques-
tion is whether the same is true under in situ conditions using
intact transfected COS cells. In intact cells the free substrate
concentration available to the enzyme might be lower be-
cause of limited cellular uptake as well as binding of iodo-
thyronine substrate to cytosolic iodothyronine-binding pro-
teins or membranes (1–2).
When D3wt or D3Cys enzyme were expressed in COS
cells, addition of increasing amounts of unlabeled T3 did not
result in saturation of the fractional deiodination of [125I]T3
(Fig. 7A). The D3Ala protein was inactive, whereas the per-
centage deiodination of T3 by D3wt and D3Cys protein were
similar. In control experiments, it was established that non-
transfected COS cells sulfate [125I]T2, and therefore the sum
of [125I]T2 and [125I]T2SO4 was used to calculate the percent-
age deiodination of T3.
When D2 enzyme was expressed in COS cells, addition of
increasing amounts of unlabeled T4 resulted in the complete
saturation of [125I]T4 deiodination, as reflected by a decrease
of [125I]T3 release into the medium (40) (Fig. 7B). In contrast,
the fractional deiodination of [125I]T4 by D3wt and D3Cys
enzyme was not saturable. The saturation of the fractional







Vmax/Km Km (nM) Vmax (pmol/
minmg)
Vmax/Km
D3wt 0.3 3.1 0.8 0.3 4.3 1.4 0.3
1 3.6 1.2 0.3 5.6 2.0 0.4
3 4.8 1.7 0.4 3.5 1.9 0.5
10 6.6 2.2 0.3 4.1 2.3 0.5
D3 placenta 1 2.8 0.3 0.1
3 3.4 0.4 0.1
10 4.1 0.5 0.1 8.0 0.6 0.07
D3Cys 0.3 4.2 5 1.2
1 15 22 1.5 265  11 11  2 0.04
3 31 46 1.5 477  67 18  2 0.04
10 33 51 1.5 570  93 21  5 0.04
FIG. 3. Effect of GTG on T3 deiodination (1 nM T3, 10 mM DTT) by
D3wt and D3Cys enzyme.
FIG. 4. Effect of pH on deiodinase activity of D3wt or D3Cys enzyme
in the presence of 1 nM T3 or T4 (closed symbols) and in the presence
of 10 nM T3 or T4 (open symbols). Each point is the mean of closely
agreeing duplicate determinations, and the experiment was per-
formed twice with similar results. The curves were obtained by fitting
the data points to a hyperbolic function and the pH optimum was
calculated.
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deiodination of T4 by D2 at high medium T4 concentrations
indicated that cellular T4 uptake did not limit its deiodina-
tion, whereas in the case of D3, uptake of T4 apparently did
limit deiodination. In this regard it is important to note that
the in vitro Km values of D2wt and D3wt for T4 are similar
(4–5 nm). The intracellular concentration of D3 might be
higher than that of available T4. Attempts to reduce the
expression level of D3 enzyme by transfecting 10-fold lower
amounts of plasmid DNA (0.2 g/well instead of 2 g/well)
gave similar results, i.e. no saturation of the deiodination of
[125I]T4 by medium T4 concentrations of up to 1 m.
Discussion
The aim of the present study was to investigate the role of
the SeC residue in the catalytic center of D3 protein. Replac-
ing the SeC residue with alanine inactivated the D3 enzyme,
as was previously also described for D1 (41) and D2 enzymes
(40, 42). Substitution of cysteine for SeC did not eliminate D3
activity but reduced the turnover number 2-fold for T3 and
6-fold for T4 deiodination. In addition, the Km for T3 in-
creased 5-fold, whereas the Km for T4 increased 100-fold in
comparison with D3wt enzyme.
The SeC residue in the catalytic center is essential for
maximal catalytic efficiency of deiodinases and other sel-
enoenzymes such as glutathione peroxidase, formate dehy-
drogenase, and thioredoxin reductase (40–42, 54–56, 58–59).
Substitution of Cys for SeC has quite variable results, pos-
sibly because of different catalytic mechanisms used by D1,
D2, and D3. The D1 enzyme exhibits ping-pong (bi)substrate
kinetics, whereas the D2 and D3 enzymes exhibit sequential
reaction kinetics (7, 18, 38, 40, 41, 60). In D1 mutation of SeC
to Cys raises the Km for rT3 only 3-fold but reduces the
substrate turnover number 100-fold (41). The SeC residue in
the catalytic center of D1 is thought to function as the iodine
acceptor, and the selenenyl iodide intermediate is the target
for reaction with propylthiouracil (38, 39, 60, 61). The thiol
group of Cys is a much weaker nucleophile than the selenol
group of SeC, thus explaining the strongly reduced efficiency
of formation of the sulfenyl iodide intermediate and there-
fore the reduced turnover of the D1Cys enzyme.
Both for D2 and D3, substitution of SeC by Cys results in
a limited decrease in turnover of the substrate T4 but a
marked increase in the Km for T4. In D2 the Km increased
1000-fold and the T4 turnover was reduced 10-fold (40, 42).
In this study the D3Cys enzyme has a 6-fold reduced turn-
over of T4 and a 100-fold increased Km for T4. We proposed
a catalytic model for D2 in which the SeC residue exerts a
nucleophilic attack to the 2-position of T4, thus forming an
intermediate complex between the SeC residue and T4 (40).
Subsequent steps involve the abstraction of iodonium by
DTT (or another thiol group containing cofactor) providing
a D2/T3 complex that will yield T3 and the unmodified
enzyme. So in this model the activated substrate is directly
reduced by the cofactor, whereas in the case of D1, the SeI
intermediate is reduced by cofactor. This model of reductive
dehalogenation of T4 by D2 might also apply to D3 enzyme.
In that case it would involve a nucleophilic attack to the
2-position of T4. In this model the lower nucleophilicity of the
SH group in Cys, compared with the SeH group in SeC
would result in a less favorable formation of the intermediate
between T4 and D2 or D3 enzyme, which is reflected in the
1000-fold (D2) or 100-fold (D3) increased Km for T4.
The decreased catalytic activity of D1 and D2 mutant en-
zymes in which Cys substitutes for SeC has been attributed
to the reduced dissociation of the sulfhydryl group at phys-
iological pH and thus to the diminished nucleophilic char-
acter of the catalytic center, compared with the wild-type
enzymes (41, 42). By comparing the actual pH activity pro-
files of D3 wt and D3Cys enzyme, no shift to more alkaline
pH values for D3Cys enzyme was observed, despite the
different pK values (5 vs. 9) of the selenol and sulfhydryl
moieties (57). So the pH dependence of D3 activity is not
simply accounted for by the dissociation of the nucleophilic
group (selenol or sulfhydryl) in the catalytic center. For thi-
oredoxin reductase the pH optimum shifted from 7 to 9 for
the mutant enzyme in which the penultimate SeC was sub-
stituted by Cys (58). For other selenoenzymes such as glu-
tathione peroxidase and formate dehydrogenase such big pH
shifts for the Cys mutant enzymes were not observed (54–
56), perhaps because these enzymes display rather broad pH
optima around 8.5. It is remarkable that the pH optimum for
D3 is close to 7 (6.7–7.1) and D3 activity is strongly reduced
at pH 8, especially with T4 as substrate.
The selenol or sulfhydryl group might interact with side
groups of other amino acid residues in the catalytic center.
These interactions could stimulate deprotonation of the sel-
enol or sulfhydryl group at physiological pH. A so-called
catalytic triad involving tryptophane and glutamine residues
stimulating SeC deprotonation has been described for glu-
tathione peroxidase (55, 62). For D1 the formation of an
essential imidazolium-selenolate ion pair was postulated on
the basis of experiments with histidine-directed reagents,
pH-dependent kinetic properties, and site-directed mu-
tagenesis studies (1, 63, 64). The existence of a catalytic triad
or an imidazolium-selenolate ion pair in D3 enzyme is spec-
ulative at the moment and needs further investigation.
The D3Cys enzyme is sensitive to GTG, and the IC50 value
is about 30-fold higher than that of D3wt enzyme. This in-
crease mirrors the change in sensitivity toward GTG of native
vs. D1Cys or D2Cys enzymes, which resulted in 100-fold
FIG. 5. Quantitation of the relative amounts of D3wt and D3Cys
protein by Western blotting. COS cell homogenates were subjected to
immunoblot analysis as described in Materials and Methods. Migra-
tion distances of molecular mass markers are indicated (kilodaltons).
To compare the relative amount of protein expressed between D3wt
and D3Cys, the homogenates containing D3Cys were diluted in ho-
mogenates from mock-transfected COS cells. The D3wt selenoprotein
was expressed approximately 50-fold less well than the D3Cys mutant.
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higher inhibitory constant values (Ki) for GTG (42, 60). For
both D1 and D3 enzymes, GTG is a competitive inhibitor,
implying that GTG interacts directly with the conserved cat-
alytic center (34, 60). However, this does not explain the
differential sensitivity toward GTG of the deiodinases, with
D1 being the most sensitive and D3 the least sensitive (65).
Also, the reduced sensitivity to GTG of D3Cys enzyme does
not necessarily imply that inhibition by GTG is selective for
the SeC residue in the catalytic center. Other Cys residues
outside the catalytic center might be involved as well.
BrAc[125I]T3 has proven to be a useful affinity label for D1,
allowing specific identification of the enzyme in microsomal
fractions of liver and kidney (44, 50, 66). Affinity labeling
with BrAc[125I]T3 was also used for the quantitation of D1
enzyme expression levels by saturation analysis, allowing
estimation of the D1 substrate turnover number in microso-
mal preparations and homogenates of transfected cells (41,
50). With regard to affinity labeling of D3 with BrAcT3 results
have been confusing (51–52, 67). Initial experiments with
brain and placenta microsomes revealed a good correlation
between affinity labeling of a 32-kDa protein (p32) and in-
activation of D3 by unlabeled BrAcT3 (51, 52). However,
when p32 was also detected in tissues with low or unde-
tectable D3 activity and p32 labeling was not prevented by
substrates of D3, it was concluded that p32 does not represent
D3 protein (51, 52). An alternative explanation for the in-
consistencies might be that in one-dimensional SDS-PAGE,
the low abundance D3 protein comigrates with an abundant
p32 protein not related to D3 (52, 67).
Despite the ambiguous results with respect to affinity la-
beling of native D3 with BrAcT3, we decided to try to label
recombinant D3 in COS or HEK cell homogenates. Although
D3 activity was inactivated with BrAcT3, we were not able
to use affinity labeling with BrAc[125I]T3 as a reliable method
to quantify the D3 content of homogenates. The labeling
intensity of D3wt and D3Cys protein was low, certainly
when compared with D1wt protein labeled under the same
experimental conditions. Possible explanations are: 1)
BrAc[125I]T3 is degraded after coupling to D3, leading to a
loss of radioactivity bound to D3; 2) the amount of D3 present
in the homogenates is too low to allow sufficient incorpo-
ration of BrAc[125I]T3; 3) BrAcT3 blocks the interaction of T3
with D3 but does not react covalently with D3 because of
unfavorable positioning toward a nucleophilic amino acid
(SeC) in the catalytic center; and 4) inner-ring deiodination
of BrAcT3 by D3 and the BrAcT2 and/or BrAcT1 thus formed
FIG. 6. A, Labeling patterns obtained
after reaction of COS cell homogenates
(100–150 g protein) containing D3wt,
D3Cys, or D1wt or control homogenates
with BrAc [125I]T3 in the presence of 10
mM DTT at 4 C, 20 C, or 37 C. Migration
distances of molecular mass markers
are indicated (kilodaltons). B, HPLC
analysis of metabolites recovered from
incubation of BrAc[125I]T3 with D3wt
enzyme, D3Cys enzyme, or human pla-
centa microsomes in P100E2D10 at 37
C. Retention times are 11 min for
BrAcT3, 9 min for BrAcT2, and 3–4 min
for T3 and T2. The peak at 7 min most
likely represents BrAc[125I]T1, al-
though this reference compound was
not synthesized. The pattern obtained
with D1wt enzyme or D2wt enzyme was
similar to that obtained with homoge-
nate from nontransfected (control) COS
cells (not shown).
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do not label D3 enzyme. We found evidence for the last
possibility, although the alternatives cannot be excluded.
Because of the inner-ring deiodination, it is clear that BrAcT3
is not optimal as affinity label for D3 protein, and improved
affinity label(s) should be developed. In contrast to our re-
sults, Salvatore et al. (34) described affinity labeling with
BrAc[125I]T3 and quantitation by saturation analysis of D3 in
homogenates of HEK-293 cells. Inner-ring deiodination of
BrAcT3 by D3 enzyme was not investigated.
From the intact cell deiodination experiments, it is clear
that D3Cys enzyme is active in situ in the presence of en-
dogenous cofactor, just as D3wt enzyme. The intracellular
actual free substrate concentrations are unknown, so detailed
kinetic studies are not possible. The lack of saturability of the
fractional T4 deiodination by D3 in contrast to D2 could be
explained if the D3 expression level is higher than that of D2.
The much longer half-life of D3, compared with D2 protein
(68), could result in a higher D3 expression level.
As shown in the present work, the replacement of SeC by
Cys results in reduced substrate turnover by D3 enzyme in
particular with T4. Moreover, when SeC was replaced by Ala
the result was complete loss of catalytic activity. These results
suggest a role for the SeC residue that is catalytic rather than
structural. In fact, the SeC residue is essential for efficient
deiodination at physiological substrate concentrations. Ad-
ditional mutagenesis experiments need to be performed to
identify residues (histidine?) that might be involved in in-
teraction(s) with the SeC residue. Increased insight in the
catalytic mechanism of D3 could form the basis for the design
of D3 specific inhibitors and/or affinity labels.
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